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The wash of CB grafts involves additional product manipulation,
risks cell loss, & delays time to infusion.We have previously reported
that albumin-dextran dilution without centrifugation is feasible &
safe in recipients of red blood cell (RBC) depleted DCBT . 20
kg. Concern remains, however, about the risk of severe infusion re-
actions. We now report our experience in 108 ‘‘no wash’’ DCBT re-
cipients using RBC depleted units for the treatment of high-risk
hematologic malignancies between 2/2006-8/2011. A ‘‘no wash’’
DCBT was planned for one additional patient who developed an
anaphylaxis-type reaction 10 mls into the first unit (grade 3 severity
CTCAE v4.0), infusion was aborted, & the graft was washed. This
patient had similar reactions to blood products. The 108 patients
transplanted with a diluted graft [median 41 years (range 6-69) &
69 kg (range 24-111)] received myeloablative (n 5 80) or non-mye-
loablative (n5 28) conditioning, calcineurin-inhibitor/mycopheno-
late mofetil prophylaxis, & 4-6/6 HLA-matched grafts. Units were
diluted a median of 8 fold (range 6-12) using 5:1 10% dextran 40-
25% human serum albumin to a median final volume of 200 ml/
unit (range 200-600). The median infused TNC x 107/kg was 2.7
(larger unit) & 2.0 (smaller unit) with a median post-thaw recovery
of 86%. Units were infused consecutively [median 45 minutes/unit
(range 15-150)] after pre-medications (acetaminophen, diphenhy-
dramine, lorazepam). Infusion reactions & engraftment of the 108
patients transplanted with a diluted graft are shown (Table). While
only 16 patients (15%) had no reactions, reactions in remaining pa-
tients were mild-moderate (10 grade 1, 36 grade 2, 46 grade 3 by
CTCAE v4.0) & were easily treated. There were no grade 4-5 reac-
tions. The most common reaction was grade 2-3 hypertension in 81
(75%) patients requiring treatment in 55 (51%) with hydralazine
&/or furosemide. This was followed by nausea &/or vomiting (n
5 16, 15%). The cumulative incidence of sustained donor engraft-
ment was high: 94% for neutrophils & 85% for platelets. DCBT
with albumin-dextran dilution of RBC depleted grafts is safe& effec-
tive with high rates of engraftment in patients . 20 kg. Our results
are likely dependent on adequate dilution, slow infusion, & prompt
infusion reaction management. Mild-moderate reactions are com-
mon but are easily treated. This approach is not recommended for
patients with prior severe reactions to blood products, or for trans-
plantation of RBC-replete units.
Table. Infusion Reactions and Engraftment After ‘‘No Wash’’
DCBT (n 5 108)
Infusion Reactions by CTCAE v4No reaction n 5 16, 15%Maximum severity grade 1 n 5 10, 9%Maximum severity grade 2 n 5 36, 33%Hypertension alone 29Hypertension+other (grd 1 bradycardia or nausea/
vomiting)6Wheezing/chest tightness 1Maximum severity grade 3 n 5 46, 43%Hypertension alone 34Hypertension+other (grd 2 chills or tachycardia; grd 1
nausea/vomiting, chest pain, hypoxia, bradycardia or
fever)12Maximum severity grade 4-5 n 5 0, 0%Cumulative Incidence of Sustained Donor Engraftment
Neutrophil engraftment by day +45
All patients: 94% (95% CI: 90-99)
Myeloablative: 94% (95% CI: 88-100); median 25 days (range 13-43)
Non-myeloablative: 96% (95% CI: 88-100); median 10 days (range 7-36)
(Continued )Table. (Continued)
Infusion Reactions by CTCAE v4
Platelet engraftment to 20,000 by day +180
All patients: 85% (95% CI: 78-92)
Myeloablative: 84% (95% CI: 75-92); median 48 days (range 30-162)
Non-myeloablative: 89% (95% CI: 77-100); median 34 days (range 9-59)24
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We previously reported the efficacy/safety outcomes of the
CLASSIC I study in older patients (pts) with R/R AML (Kantarjian,
EHA 2011). In this report, we evaluate the outcomes of HSCT after
Clo+Ara-C or Ara-C alone in CLASSIC I.
CLASSIC I was a randomized, double-blind trial that compared
Clo+Ara-C toAra-C inpts$55 yearswithR/RAML.Ptswere random-
ized to either Clo 40 mg/m2 or placebo followed by Ara-C 1 g/m2 each
for 5 consecutive days. While the primary endpoint of OS did not
differ between arms, there were statistically significant improve-
ments in the secondary endpoints (ORR, CR & EFS) in the
Clo+Ara-C arm. In this post-hoc analysis, patient characteristics
and safety were analyzed for pts who underwent HSCT. Since the
median time to HSCT was 3.8 months from the initiation of the
study drug, a 4-month landmark analysis was conducted to evaluate
OS following HSCT.
Among 320 pts with centrally confirmed AML (median age,
67yrs), 66 (21%; median age 63.5 yrs) underwent HSCT
[Clo+Ara-C: n 5 34; Ara-C: n 5 32]. Of these, 47 pts (71%) went
to HSCT in CR; 36 in CR from study drug [Clo+Ara-C: n 5 22
vs Ara-C: n 5 14] and 11 in CR from alternative therapy. 64 pts re-
ceived an allogeneic transplant [sibling donor: n 5 46 (70%), unre-
lated donor: n 5 18 (27%)] and 2 (3%) were autologous
transplants. Preparative regimens included myeloablative in 22 pts
(33%) and reduced intensity conditioning/non-myeloablative in 43
pts (65%).
Multiple analyses were consistent with a survival benefit ofHSCT:
a naive estimate comparing OS in pts with and without HSCT; a 4-
month landmark analysis comparing OS in pts with and without
HSCT; and landmark analyses assessing the impact of HSCT on
OS for patients who achieved CR. Although there was evidence
that HSCT was associated with longer survival, there was little evi-
dence of a differential effect across the treatment arms (interaction p
5 0.32 [not shown]). Post HSCT safety findings were similar across
treatment arms and raised no new concerns.
